{
    "clinical_study": {
        "@rank": "11633", 
        "arm_group": {
            "arm_group_label": "Placebo and BAY1067197", 
            "arm_group_type": "Experimental", 
            "description": "Patients will get both treatment 1 and 2"
        }, 
        "brief_summary": {
            "textblock": "This is a study to investigate the safety and tolerability of the partial A1 agonist\n      BAY1067197 in patients with chronic heart failure. BAY1067197 will be applied as a single\n      dose of 30 mg in addition to standard therapy including a beta-blocker. The aim of the study\n      is to assess if a single oral dose of 30 mg BAY1067197 is well tolerated when given on top\n      of standard therapy for heart failure, particularly \u00df-blocker treatment."
        }, 
        "brief_title": "Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including \u00df-blocker", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stable systolic heart failure (heart failure with reduced ejection fraction, heart\n             failure with reduced ejection fraction [HFrEF]; New York Heart Association [NYHA]\n             I-III) in sinus rhythm with a documented ejection fraction (EF) \u226445% within the last\n             3 months\n\n          -  Stable standard heart failure (HF) therapy including intermediate to high dose\n             \u03b2-blocker with either \u2265 95 mg metoprolol succinate (controlled release tablet), \u2265 5mg\n             Bisoprolol (immediate release [IR] -tablet) or \u22655mg Nebivolol (IR tablet) for at\n             least 4 weeks. Additional intake of angiotensin-converting enzyme (ACE) inhibitors or\n             angiotensin receptor blockers and optional aldosterone-receptor antagonists,\n             diuretics or digitalis is allowed\n\n          -  Men or confirmed postmenopausal women (defined as being amenorrheic for longer than 2\n             years with an appropriate clinical profile, e.g. age appropriate and a history of\n             vasomotor symptoms) or women without childbearing potential based on surgical\n             treatment such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy\n             (documented by medical report verification). Men enrolled in this study must agree to\n             use adequate barrier birth control measures during the treatment period of the study\n             and for 12 weeks after receiving the investigational medicinal product (IMP)\n\n          -  Male patients must agree not to act as sperm donor for 12 weeks after dosing\n\n          -  Ethnicity: White\n\n          -  Body mass index (BMI): above/equal 18.0 and below/equal 29.9 kg/m\u00b2\n\n          -  Age: 18 to 75 years (inclusive) at the first screening visit\n\n        Exclusion Criteria:\n\n          -  Biventricular pacing/active cardiac resynchronization therapy (CRT) device\n\n          -  Dependency on pacemaker or implantable cardioverter-defibrillator (ICD) device with\n             pacemaker dependency (a paced ventricular rhythm > 5% of heart activity)\n\n          -  A history of relevant diseases of vital organs other than the heart, of the central\n             nervous system or other organs\n\n          -  Known hypersensitivity to the study preparations (active substances or excipients of\n             the preparations) or to any other \u03b2-blocker\n\n          -  Current or history of AV-Block > I\u00b0\n\n          -  Unstable condition, indicated by requirement of IV drug (diuretic, inotrope, etc.) or\n             NYHA IV\n\n          -  Acute Coronary Syndrome (defined as unstable angina [UA], non-ST elevation myocardial\n             infarction [NSTEMI], ST elevation myocardial infarction [STEMI]) within 3 months\n             prior to first study drug administration\n\n          -  History of asthma or chronic obstructive pulmonary disease (COPD) \u2265 global initiative\n             for chronic obstructive lung disease (GOLD) II and/or allergic asthma\n\n          -  Women of childbearing potential, pregnancy or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01945606", 
            "org_study_id": "16718", 
            "secondary_id": "2013-001287-34"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo and BAY1067197", 
                "description": "Oral administration of placebo tablets", 
                "intervention_name": "Placebo (treatment 1)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo and BAY1067197", 
                "description": "Oral administration of a single dose of 30 mg (3\u00d710 mg Tablet) BAY1067197", 
                "intervention_name": "BAY1067197 (treatment 2)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 4, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Groningen", 
                    "country": "Netherlands", 
                    "zip": "9700 RB"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Blind, Placebo Controlled Pilot Study to Explore the Safety and Tolerability of a Single Oral Dose of 30 mg BAY1067197 in Patients With Chronic Heart Failure on the Background of Preexisting Beta-blocker Therapy", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with occurrence of AV-Block > I\u00b0", 
            "safety_issue": "Yes", 
            "time_frame": "up to 48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01945606"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic profile determined by tmax", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours"
            }, 
            {
                "measure": "Pharmacokinetic profile determined by t1/2", 
                "safety_issue": "No", 
                "time_frame": "up to 22 days"
            }, 
            {
                "measure": "Heart rate", 
                "safety_issue": "No", 
                "time_frame": "multiple time points up to 24 hours"
            }, 
            {
                "measure": "Blood pressure", 
                "safety_issue": "No", 
                "time_frame": "multiple time points up to 24 hours"
            }, 
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "up to 48 hours"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}